Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus Fulvestrant in HR+/HER2- MBC post-CDK4/6i
NCT04318223Phase 2Unknown
- Sponsor
- Consorzio Oncotech
- Start
- Jul 2019
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in breast cancer, sponsored by Consorzio Oncotech. Primary endpoints: Clinical Benefit Rate at 48 months and Quality of Life at 48 months. Status: unknown.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04318223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04318223.